{
  "@context": "http://id.who.int/icd/contexts/contextForLinearizationEntity.json",
  "@id": "http://id.who.int/icd/release/11/2024-01/mms/1632334328",
  "parent": [
    "http://id.who.int/icd/release/11/2024-01/mms/1136270486"
  ],
  "browserUrl": "https://icd.who.int/browse/2024-01/mms/en#1632334328",
  "code": "8A61.00",
  "source": "http://id.who.int/icd/entity/1632334328",
  "classKind": "category",
  "postcoordinationScale": [
    {
      "@id": "http://id.who.int/icd/release/11/2024-01/mms/1632334328/postcoordinationScale/hasManifestation",
      "axisName": "http://id.who.int/icd/schema/hasManifestation",
      "requiredPostcoordination": "false",
      "allowMultipleValues": "AllowAlways",
      "scaleEntity": [
        "http://id.who.int/icd/release/11/2024-01/mms/539646260"
      ]
    }
  ],
  "title": {
    "@language": "en",
    "@value": "Pyridoxal dependent epilepsy"
  },
  "definition": {
    "@language": "en",
    "@value": "Pyridoxal 5-phosphate dependent epilepsy usually presents with neonatal intractable seizures and is diagnosed by cerebrospinal fluid (CSF) analysis, gene testing, and clinical response. The majority of patients have pyridoxamine 5'-phosphate oxidase (PNPO) gene disease causing mutations. Early diagnosis and effective treatment can lead to a relatively favourable neurodevelopmental outcome."
  },
  "relatedEntitiesInMaternalChapter": [
    "http://id.who.int/icd/entity/564191997"
  ],
  "relatedEntitiesInPerinatalChapter": [
    "http://id.who.int/icd/entity/2083324835"
  ],
  "indexTerm": [
    {
      "label": {
        "@language": "en",
        "@value": "Pyridoxal dependent epilepsy"
      }
    }
  ]
}